NDAINHALATIONSPRAY, METERED
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STIOLTO RESPIMAT is a fixed-dose combination of tiotropium bromide (long-acting muscarinic antagonist) and olodaterol (long-acting beta-2 agonist) delivered via metered-spray inhalation. It is indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The dual mechanism provides bronchodilation through complementary pathways to improve airflow and reduce exacerbations.
$432MPart D
Peak4.3 years to LOEPeak-stage product with substantial Part D spending ($432M in 2023) suggests stable commercial operations and mature team infrastructure in respiratory.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on STIOLTO RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.